Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 265 | 6K |
| Gross Profit | -280 | -286 | -303 | -295 | 1K |
| Operating Income | -10K | -22K | -30K | -23K | -62K |
| EBITDA | -10K | -22K | -30K | -12K | 20K |
| Net Income | 128K | -22K | -31K | -13K | 19K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0003
+0.00% today
1Y Change
+20.00%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rimrock Gold Corp. (RMRK) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 20.0% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin 0.0% and ROIC 8.8%. Valuation is more restrained than many high-expectation growth names at P/E 5.7. Stock Foundry combines RMRK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RMRK
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RMRK Max Drawdown
-60.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RMRK and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$5.7K
+2061.9% YoY
FY Net Income
$19.3K
+251.4% YoY
Free Cash Flow
-$49.8K
-837.7% YoY
Revenue Growth
+0.0%
EPS Growth
+0.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 265 | 6K |
| Gross Profit | -280 | -286 | -303 | -295 | 1K |
| Operating Income | -10K | -22K | -30K | -23K | -62K |
| EBITDA | -10K | -22K | -30K | -12K | 20K |
| Net Income | 128K | -22K | -31K | -13K | 19K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 5K | 13K | 13K | 14K | 4K |
| Total Liabilities | 277K | 413K | 391K | 385K | 362K |
| Shareholder Equity | -272K | -400K | -378K | -371K | -358K |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | 0 | 0 | 0 | 0 | 0 |
Cash flow positioning
Latest Full Year
Operating Cash Flow
48K
-803.8% YoY
Capital Expenditures
2K
Free Cash Flow
50K
-837.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-49.2%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.